Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Regeneron Pharmaceuticals Inc

+ Add to Watchlist

REGN:US

513.880 USD 2.120 0.41%

As of 20:10:00 ET on 05/22/2015.

Snapshot for Regeneron Pharmaceuticals Inc (REGN)

Open: 513.740 Day's Range: 513.500 - 519.459 Volume: 771,492
Previous Close: 516.000 52wk Range: 269.500 - 519.459 1-Yr Rtn: +72.58%

Stock Chart for REGN

No chart data available.
  • REGN:US 513.880
  • 1D
  • 1M
  • 1Y
516.000
Interactive REGN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for REGN

Current P/E Ratio (ttm) 154.0210
Estimated P/E(12/2015) 45.9478
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) 3.3364
Est. EPS (USD) (12/2015) 11.1840
Est. PEG Ratio 2.2297
Market Cap (M USD) 53,072.24
Shares Outstanding (M) 101.31
30 Day Average Volume 778,025
Price/Book (mrq) 18.2263
Price/Sale (ttm) 16.9902
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/05/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for REGN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for REGN

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders.

Leonard S Schleifer "Len"President/CEO/Co-FounderGeorge D YancopoulosPres:Laboratories
Neil StahlExec VP:Research & DevelopmentJoseph J Larosa "Joe"Senior VP/Secy/General Counsel
More Company Profile & Key Executives for REGN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil